BioLineRx (BLRX) Beginning Cash Balance (2013 - 2025)

BioLineRx's Beginning Cash Balance history runs 13 years deep, the most recent figure standing at $10.4 million for Q1 2025.

• On a quarterly basis, Beginning Cash Balance rose 145.26% year-over-year to $10.4 million in Q1 2025; TTM through Dec 2025 was $10.4 million, a 145.26% increase from a year earlier, with the FY2025 full-year figure at $10.4 million, up 145.26% from the prior year.
• Beginning Cash Balance grew to $10.4 million in Q1 2025 per BLRX's latest filing, from $4.3 million in the prior quarter.
• Across five years, Beginning Cash Balance topped out at $16.8 million in Q1 2021 and bottomed at $4.3 million in Q1 2024.
• The 5-year median for Beginning Cash Balance is $10.6 million (2023), against an average of $11.0 million.
• Across the five-year window, Beginning Cash Balance surged 217.75% in 2021 and sank 59.81% in 2024, its largest moves.
• Year by year, Beginning Cash Balance stood at $16.8 million in 2021, then dropped by 22.82% to $13.0 million in 2022, then dropped by 18.5% to $10.6 million in 2023, then plunged by 59.81% to $4.3 million in 2024, then soared by 145.26% to $10.4 million in 2025.
• Per Business Quant, the three latest BLRX Beginning Cash Balance figures stand at $10.4 million (Q1 2025), $4.3 million (Q1 2024), and $10.6 million (Q1 2023).